In Vivo CAR-T Development Service with LNP-DNA Technology

Q: How is in vivo CAR-T delivery different from traditional CAR-T therapy?

In vivo delivery bypasses ex vivo cell expansion, directly engineering T cells within the body, reducing manufacturing time and logistical complexity. Contact us for specific workflow details.

Online Inquiry

Background Service What We Can Offer Workflow Highlights Published data FAQs Contact

Creative Biolabs offers a comprehensive In Vivo CAR-T Development Service using LNP-DNA technology to accelerate immunotherapy programs. Our platform enables the direct generation of functional CAR-T cells in the body by combining optimized lipid nanoparticle DNA delivery, T cell specific targeting, and scalable in vivo engineering strategies. We provide end-to-end support, including DNA construct design, nanoparticle formulation, in vivo delivery optimization, CAR expression validation, and functional assessment. This approach bypasses lengthy ex vivo manufacturing, enhances CAR expression persistence, and promotes efficient immune-cell targeting, providing researchers with a rapid, robust, and translational pathway toward next-generation in vivo CAR-T therapeutics.

Introduction of In Vivo CAR-T Development with LNP-DNA Technology

In vivo CAR-T development using LNP-DNA offers a promising alternative to conventional ex vivo CAR-T manufacturing. By delivering CAR-encoding DNA directly to T cells within the body, it shortens development timelines and improves accessibility. The LNP mediated DNA delivery can achieve functional CAR-T populations with controlled expression and tumor-specific activity, supporting its potential for clinical translation.

Creative Biolabs' Service

Creative Biolabs provides a fully integrated solution to design, produce, and validate in vivo CAR-T therapy using LNP-DNA systems. Our platform enables clients to bypass traditional ex vivo manufacturing by delivering CAR-encoding DNA directly to target T cells in vivo, generating functional CAR-T populations capable of tumor-specific cytotoxicity. This approach improves therapeutic efficiency, reduces manufacturing complexity, and shortens project timelines. Our team supports clients from construct design to in vivo validation, ensuring safety, specificity, and scalability.

Discover How We Can Help - Request a Consultation.

Technology Platforms

Creative Biolabs leverages a range of advanced platforms to support the development and analysis of in vivo CAR-T therapies using LNP-DNA systems. Our capabilities include:

Lipid Nanoparticle Engineering Platforms: Optimized formulations for efficient DNA encapsulation, controlled release, and cell-specific targeting.
In Vivo Imaging & Tracking Systems: Non-invasive monitoring of CAR-T distribution, persistence, and expansion in preclinical models.
Immunoassays: Quantitative detection of CAR expression, cytokine profiles, and immune cell activation to evaluate therapeutic efficacy.
Genomic and Transcriptomic Analysis Tools: Assess integration patterns, gene expression levels, and off-target effects to ensure safety and functional performance.

Engineering Workflow in Our Service

Required Starting Materials:

CAR construct sequences (plasmid or minicircle DNA).
Source information for patient or donor T cells.

Key Steps Involved:

Workflow of In Vivo CAR-T Development with LNP-DNA Technology. (Creative Biolabs Original)

Key Advantages

Customized in vivo CAR-T design and LNP-DNA formulation tailored to your therapeutic target and research goals.
One-stop service from CAR construct optimization, nanoparticle engineering, to preclinical in vivo validation.
Flexible experimental design to accommodate humanized or syngeneic models for functional CAR-T assessment.
Dedicated consultation and technical support to guide your project from initial concept to actionable preclinical data.

Data Support

This research focuses on developing a vaccine for Lyme disease, a growing public health concern. Scientists created a novel vaccine using a DNA platform encapsulated in lipid nanoparticles, which codes for a key bacterial protein. In mouse models, this vaccine successfully triggered a strong immune response and provided effective protection against infection, preventing both bacterial dissemination and associated heart inflammation.

Fig.1 Immune response to DNA-LNP vaccines in mice. (OA Literature) Fig.1 Immunogenicity of DNA-LNP vaccines in mice.¹

FAQs

How is in vivo CAR-T delivery different from traditional CAR-T therapy?

In vivo delivery bypasses ex vivo cell expansion, directly engineering T cells within the body, reducing manufacturing time and logistical complexity. Contact us for specific workflow details.

What safety measures are in place with LNP-DNA CAR-T?

Our formulations are optimized for T cell specificity, and expression can be tuned with inducible promoters or transient transposase systems to minimize off-target activity.

Can this service accommodate patient-specific CAR designs?

Yes. Clients provide their CAR constructs and target sequences, which we integrate into tailored LNP formulations for in vivo delivery.

How does LNP-DNA compare to viral-based CAR-T approaches?

LNP-DNA reduces production complexity, avoids viral vectors, and allows more flexible dosing schedules while maintaining robust in vivo CAR-T generation.

Partner With Us

Creative Biolabs provides an end-to-end solution for In Vivo CAR-T Development with LNP-DNA Technology, from construct design to preclinical validation. We combine expertise in lipid nanoparticle engineering, T cell biology, and CAR-T development to deliver a reliable, scalable in vivo solution. We leverage published data and proprietary design strategies to maximize CAR expression and functional activity while maintaining safety. Our services streamline in vivo CAR-T generation, maximize functional activity, and reduce development timelines.

Contact our team for more information or to discuss your project.

Reference

Pfeifle, Annabelle et al. "DNA lipid nanoparticle vaccine targeting outer surface protein C affords protection against homologous Borrelia burgdorferi needle challenge in mice." Frontiers in immunology vol. 14 1020134. 16 Mar. 2023. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2023.1020134.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.